調査レポートカテゴリー： visiongain, 世界, 医療/バイオ

Pharma Leader Series: Top Stem Cell Technology Companies 2014-2024

主要な幹細胞（ステムセル）技術企業分析（2014-2024）

◆タイトル：Pharma Leader Series: Top Stem Cell Technology Companies 2014-2024
◆商品コード：Visiongain-4052643
◆調査・発行会社：visiongain
◆発行日：2014年3月
◆ページ数：171
◆レポート形式：PDF / 英語
◆納品方法：Eメール
◆調査対象地域：グローバル
◆販売価格オプション（消費税別）
Single user licence（1名使用）GBP1,799 ⇒換算￥273,448見積依頼/購入/質問フォーム
Dept Licence（部署内共有可）GBP2,999 ⇒換算￥455,848見積依頼/購入/質問フォーム
Site Licence（同一国内社内共有可）GBP4,999 ⇒換算￥759,848見積依頼/購入/質問フォーム
※Single UserとDept Licence(Five User)の場合、DRM（デジタル著作権管理）付PDFファイルです。認証されたPC上のみでの閲覧と、PDF閲覧期限は購入日より1年となります。Dept Licence(Five User)は印刷できますが、Single Userは印刷できません。Site Licence/Global Site Licenseの場合は、閲覧・印刷制限はありません。
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※商品の納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。（振込先：三菱東京UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はvisiongainの日本における正規販売代理店です。

 【レポートの概要】

本調査レポートでは、"主要な幹細胞（ステムセル）技術企業分析（2014-2024）"について調査・分析し、エグゼクティブサマリー、各企業分析、市場動向、市場環境分析、研究開発パイプライン分析、専門家の見解、結論などの情報をお届けいたします。

Stem cell developers and producers – discover companies’ R&D and revenue prospects
Who are the top stem cell developers and producers? And what are their sales potentials? Visiongain’s new report shows you their outlooks from 2014. There you discover therapies, sales results, trends, opportunities, and predictions of revenues.
That way you find data and analysis on cellular technologies with potential to improve human medicine. Our study analyses 22 leading companies in the US, Europe, Israel, and Asia. There you hear how stem cell producers can gain and progress, discovering what’s possible.
Read on to see those organisations and find what their market could be worth.
Forecasts and other data helping you stay ahead for those technologies and applications
In our new study you find analytical profiles of 22 stem cell companies, and analyses of that overall industry. So you see results, research and development (R&D), growth rates, and revenue forecasting. Discover, from 2014, those firms’ commercial prospects.
There you also gain 106 tables, 38 charts, and two interviews with companies.
See now how you can benefit your research, analyses, and decisions, also saving time and helping your influence for those treatments. The following sections explain.
Company profiles – activities, competition, and operational outlooks
The contents of company profiles differ, but our study covers details such as these:
• Technologies, R&D pipelines, products, and financial performance
• Acquisitions, alliances, technological applications, and clinical developments
• Strengths, weaknesses, opportunities, and threats to business (SWOT forces)
• Revenues to 2024 (stem cell forecasts for 18 companies).
Discover there what participants do, provide, and seek, helping you stay ahead. You assess how they can perform to 2024.
That new investigation divides the industry into three regional blocks.
United States (US) – leading organisations and their potentials
First our study gives you discussions, financial analyses, and commercial outlooks for 10 US-based stem cell firms, including these:
• Advanced Cell Technology (ACT)
• BrainStorm Cell Therapeutics
• Bioheart
• International Stem Cell Corporation (ISCO)
• NeoStem
• Osiris Therapeutics.
There you hear what the future holds for those healthcare companies, including trends and revenue predictions to 2024.
The report then analyses Europe and Israel, showing that region’s activities and potential.
Companies based in Europe and Israel – what successes can they achieve?
Next our analysis shows you progress and revenue outlooks to 2024 for 7 European and Israeli companies, including these:
• apceth
• Cardio3 BioSciences
• Cell Cure Neurosciences
• TiGenix
• Gamida Cell
• Pluristem Therapeutics.
Our work shows you where sales growth can occur. Many opportunities remain in that industry, with high, expanding revenues possible from this decade. There you see where sales occur and what they mean. You also explore plans for launching products.
That study then analyses the Asian segment, explaining its potential.
Stem cell specialists based in the Asia-Pacific region
You also discover outlooks for 5 top researchers, developers, and producers of stem cells in Asia:
• Anterogen
• MEDIPOST
• Mesoblast
• Pharmicell
• Stempeutics Research.
Our report shows potentials of that industry segment. You see possibilities for advancing technology and raising business performance, assessing where money lies.
That study also covers the overall world industry, showing you its revenue potential.
Predictions for the worldwide stem cells market – what’s possible by 2018 and beyond?
Our report also forecasts revenues to 2024 for the overall world stem cells industry and five submarkets:
• Cancer treatment (oncology)
• Cardiovascular (CV) applications
• Central nervous system (CNS) uses
• Other therapy using those biological agents
• Non-therapeutic cellular products.
There you find overall revenues reaching $12.2bn in 2018, with high growth to 2024. You also examine forces driving and restraining that industry – social, technological, economic, and political issues.
See, then, what the future holds for those technological advances.
Technologies shaping the stem cells industry and market – explore progress and potential
Our study explains those cellular technologies and their benefits. You explore these advances and many others:
• Human embryonic stem cells – aiding tissue repair and regeneration
• Autologous and allogeneic agents, including T cell therapy (T lymphocytes)
• Genetically-modified treatment for cancer
• Cell engraftment in bone marrow transplantation
• Umbilical cord blood – applications of that tissue and cell banking
• Non-therapeutic pharma applications – cellular screening in drug development.
There you also get interviews with companies, finding information to help you stay ahead on commercial progress, outlooks, and future trends. That way, avoid missing out.
Ways Pharma Leader Series: Top Stem Cell Technology Companies 2014-2024 helps
In particular, our new investigation gives you this knowledge to benefit your work:
• Profiles of 22 leading companies in North America, Europe, Israel, and Asia – assess products, R&D progress, results, strategies, and partnerships
• Revenues to 2024 for that market at world level and by submarket – discover potential sales, seeing the commercial possibilities
• Competition, needs, and opportunities – explore what affects the stem cells industry, finding what influences participants’ sales and determines their futures
• Interviews with developers and producers of stem cells – find what participants from that industry think, say, and do, helping you stay ahead.
Information there found nowhere else, benefiting your understanding, work and authority
Our report gives independent data. There you get competitive intelligence found only in that work, finding where progress and money lie. You examine the commercial possibilities.
With that original research and analysis you’re less likely to fall behind in information or miss opportunity. There see how you could save time and effort. And benefit your plans, decisions, and influence, helping gain competitive advantages.
So by trying our new analysis on stem cells you explore trends, R&D, and sales predictions. Avoid missing out – please get that report here now.

【レポートの目次】

1. Executive Summary
1.1 Top Stem Cell Technology Companies: Overview of Findings
1.2 Report Contents
1.3 Study Methods – Research and Analysis
1.4 Scope and Format of Report
2. Leading US Stem Cell Technology Companies, 2014
2.1 Aastrom Biosciences
2.1.1 Stem Cell Technology Platform
2.1.2 Aastrom: Stem Cell Pipeline, 2014
2.1.2.1 Ixmyelocel-T: Patient-Specific Therapy Reduces Risk of Rejection
2.1.2.2 Orphan Designation to Accelerate Product Development
2.1.3 Sales and Recent Performance, 2012
2.1.4 Aastrom: Stem Cell SWOT Analysis, 2014-2024
2.1.5 Aastrom: Stem Cell Revenue Forecast, 2014-2024
2.2 Advanced Cell Technology (ACT)
2.2.1 Stem Cell Technology Platform
2.2.2 ACT: Stem Cell R&D Pipeline, 2014
2.2.2.1 Human Embryonic Stem Cells: Aiding Tissue Repair
2.2.3 Sales and Recent Performance, 2012
2.2.4 ACT: Stem Cell SWOT Analysis, 2014-2024
2.2.5 ACT: Stem Cell Revenue Forecast, 2014-2024
2.3 Bioheart
2.3.1 Bioheart: Stem Cell Pipeline, 2014
2.3.2 Sales and Recent Performance, 2012
2.3.3 Bioheart: Stem Cell SWOT Analysis, 2014-2024
2.3.4 Bioheart: Stem Cell Revenue Forecast, 2014-2024
2.3.4.1 Increased Activity Abroad Will Help Bioheart Attract Investment
2.4 BrainStorm Cell Therapeutics
2.4.1 Brainstorm Cell Therapeutics: Stem Cell Pipeline, 2014
2.4.2 Brainstorm Cell Therapeutics: Stem Cell SWOT Analysis, 2014-2024
2.4.3 Brainstorm Cell Therapeutics: Stem Cell Revenue Forecast, 2014-2024
2.4.3.1 Government Grant Will Provide Much Needed Investment
2.5 California Stem Cell Inc.
2.5.1 California Stem Cell: Stem Cell Pipeline, 2014
2.5.2 California Stem Cell: Stem Cells SWOT Analysis, 2014-2024
2.6 International Stem Cell Corporation (ISCO)
2.6.1 ISCO: Stem Cell Pipeline, 2014
2.6.2 Sales and Recent Performance, 2012
2.6.3 ISCO: Stem Cells SWOT Analysis, 2014-2024
2.6.4 Cosmetic Subsidiary Expands Into Asian Market
2.7 NeoStem
2.7.1 NeoStem: Stem Cell Pipeline, 2014
2.7.1.1 AMR-001: Highly Efficacious Therapy for AMI
2.7.1.2 T-Cell Therapy: Using Autologous Immune Cells as Therapy
2.7.1.3 VSEL Technology: Promoting Cell Migration to Site of Damage
2.7.2 Sales and Recent Performance, 2012
2.7.3 NeoStem: Stem Cell SWOT Analysis, 2014-2024
2.7.4 NeoStem: Stem Cell Revenue Forecast, 2014-2024
2.8 Neuralstem
2.8.1 Stem Cell Technology Platform
2.8.2 Neuralstem: Stem Cell Pipeline, 2014
2.8.2.1 NSI-566: Potential Therapy in Multiple Neurological Disorders
2.8.2.2 NSI-189: Deriving Cells from the Hippocampal Region
2.8.3 Sales and Recent Performance, 2012
2.8.4 Neuralstem: Stem Cell SWOT Analysis, 2014-2024
2.8.5 Neuralstem: Stem Cell Revenue Forecast, 2014-2024
2.9 Medistem
2.9.1 Medistem: Stem Cell Pipeline, 2014
2.9.2 Medistem: Stem Cell SWOT Analysis, 2014-2024
2.9.3 Medistem: Stem Cell Revenue Forecast, 2014-2024
2.9.3.1 Expansion of Clinical Indications Through Acquisition
2.10 Osiris Therapeutics
2.10.1 Osiris Therapeutics: Stem Cell Products
2.10.2 Osiris Therapeutics: Stem Cell Pipeline, 2014
2.10.3 Sales and Recent Performance, 2012
2.10.4 Osiris Therapeutics: Stem Cell SWOT Analysis, 2014-2024
2.10.5 Osiris Therapeutics: Stem Cell Revenue Forecast, 2014-2024
2.11 Other US Companies Operating in the Stem Cells Technology Industry, 2014
3. Top European and Israeli Stem Cell Technology Companies, 2014
3.1 Apceth
3.1.1 Apceth: Stem Cell Pipeline, 2014
3.1.1.1 Alecmestencel-T: Options for Autologous and Allogeneic Therapy
3.1.1.2 Agenmestencel-T: Genetically-modified Therapy for Cancer
3.1.2 Apceth: Stem Cell SWOT Analysis, 2014-2024
3.1.3 Apceth: Stem Cell Revenue Forecast, 2014-2024
3.2 Cardio3 BioSciences
3.2.1 Cardio3 BioSciences: Stem Cell Pipeline, 2014
3.2.1.1 C-Cure®: Creating New Muscle Cells
3.2.2 Cardio3 BioSciences: Stem Cell SWOT Analysis, 2014-2024
3.2.3 Cardio3 BioSciences: Stem Cell Revenue Forecast, 2014-2024
3.3 Cell Cure Neurosciences
3.3.1 Cell Cure Neurosciences: Stem Cell Pipeline, 2014
3.3.2 Cell Cure Neurosciences: Stem Cell SWOT Analysis, 2014-2024
3.4 TiGenix
3.4.1 Stem Cell Technology Platform
3.4.2 TiGenix: Stem Cell Products
3.4.2.1 ChondroCelect: One of Few Marketed Stem Cell Products
3.4.3 TiGenix: Stem Cell Pipeline, 2014
3.4.3.1 Cx601: Promoting Natural Close of Fissure
3.4.3.2 Cx611: Landmark Results of a Cell Therapy in Rheumatoid Arthritis
3.4.3.3 Cx621: Novel, Painless Route of Administration?
3.4.4 Sales and Recent Performance, 2012
3.4.5 TiGenix: Stem Cell SWOT Analysis, 2014-2024
3.4.6 TiGenix: Stem Cell Revenue Forecast, 2014-2024
3.5 Gamida Cell
3.5.1 Stem Cell Technology Platform
3.5.1.1 Copper Chelator-based Technology
3.5.1.2 Nicotinamide (NAM) Platform
3.5.2 Gamida Cell: Stem Cell Pipeline, 2014
3.5.2.1 StemEx: Huge Market Potential in Patient Numbers
3.5.2.2 NiCord: Transplanting Two Units of Umbilical Cord Blood
3.5.3 Gamida Cell: Stem Cell SWOT Analysis, 2014-2024
3.5.4 Gamida Cell: Stem Cell Revenue Forecast, 2014-2024
3.6 Pluristem Therapeutics
3.6.1 Stem Cell Technology Platform:
3.6.2 Pluristem Therapeutics: Stem Cell Pipeline, 2014
3.6.2.1 PLX-PAD: Clinical Hold Notification May Delay Approval
3.6.2.2 PLX-RAD: Accelerating Cell Engraftment in Bone Marrow Transplantation
3.6.3 US and Korea Licence Partnerships to Drive Revenue
3.6.4 Sales and Recent Performance, 2013
3.6.5 Pluristem Therapeutics: Stem Cell SWOT Analysis, 2014-2024
3.6.6 Pluristem Therapeutics: Stem Cell Revenue Forecast, 2014-2024
3.7 ReNeuron
3.7.1 ReNeuron: Stem Cell Technology Platform
3.7.2 ReNeuron: Stem Cell Pipeline, 2014
3.7.2.1 ReN001: Groundbreaking Therapy in Development
3.7.2.2 ReN009: Avoiding Possible Limb Amputation
3.7.2.3 ReN003: Grant and Partnership with Leading US University Will Drive Development
3.7.3 Sales and Recent Performance, 2013
3.7.4 ReNeuron: Stem Cell SWOT Analysis, 2014-2024
3.7.5 ReNeuron: Stem Cell Revenue Forecast, 2014-2024
3.8 Other European and Israeli Companies Operating in the Stem Cells Technology Industry, 2014
4. Top Asia-Pacific Stem Cell Technology Companies, 2014
4.1 Anterogen
4.1.1 Anterogen: Stem Cell Products
4.1.1.1 Cupistem®: World’s First MSC Product From Adipose Tissue
4.1.1.2 Queencell®:
4.1.2 Anterogen: Stem Cell Pipeline, 2014
4.1.3 Anterogen: Stem Cell SWOT Analysis, 2014-2024
4.2 MEDIPOST
4.2.1 Stem Cell Technology Platform
4.2.2 MEDIPOST: Stem Cell Pipeline, 2014
4.2.2.1 Cartistem: A Top 25 Science Technology
4.2.2.2 Neurostem: Restorative Therapy for Neurological Disease
4.2.2.3 Pneumostem: Treatment for Paediatric Population
4.2.2.4 Promostem: Encouraging Engraftment of Cells Following Transplantation
4.2.3 Sales and Recent Performance, 2014
4.2.4 MEDIPOST: Stem Cell SWOT Analysis, 2014-2024
4.2.5 MEDIPOST: Stem Cell Revenue Forecast, 2014-2024
4.2.5.1 Collaboration with an Indian Company Expands Reach in Asia
4.3 Mesoblast
4.3.1 Stem Cell Technology Platform
4.3.2 Mesoblast: Stem Cell Pipeline, 2014
4.3.2.1 Immunology and Inflammatory Diseases
4.3.2.2 Spinal Disease
4.3.2.3 Cardiac and Vascular Disease
4.3.2.4 Oncology
4.3.2.5 Other Indications
4.3.3 Sales and Recent Performance, 2012
4.3.4 Mesoblast: Stem Cell SWOT Analysis, 2014-2024
4.3.5 Mesoblast: Stem Cell Revenue Forecast, 2014-2024
4.4 Pharmicell
4.4.1 Pharmicell: Stem Cell Products
4.4.1.1 Hearticellgram-AMI: World First Cell Therapy for Acute Myocardial Infarction
4.4.2 Pharmicell: Stem Cell Pipeline, 2014
4.4.3 Sales and Recent Performance, 2012
4.4.4 Pharmicell: Stem Cell SWOT Analysis, 2014-2024
4.4.5 Pharmicell: Stem Cell Revenue Forecast, 2014-2024
4.5 Stempeutics Research
4.5.1 Stem Cell Technology Platform
4.5.2 Stempeutics Research: Stem Cell Pipeline, 2014
4.5.2.1 Stempeucel®: Launch in Fast-Growing Asian Markets
4.5.2.2 Stempeucare™: Cosmetic Growth Factor Treatment
4.5.3 Stempeutics Research: Stem Cell SWOT Analysis, 2014-2024
4.5.4 Stempeutics Research: Stem Cell Revenue Forecast, 2014-2024
4.5.4.1 Cipla Alliance to Drive Revenue as Wider Population Targeted
5. The World Stem Cell Technology Market, 2014-2024
5.1 The World Stem Cell Technology Market, 2012
5.2 The World Stem Cell Technology Market: Revenue Forecast to 2024
5.2.1 What Will Drive The World Stem Cell Technology Market Between 2014 and 2024?
5.2.2 What Factors are Likely to Restrain the World Stem Cell Technology Market Between 2014 and 2024?
5.3 The Stem Cell Technology Market: Revenue Forecast by Therapeutic Application, 2014-2024
5.3.1 How Will Market Shares of Leading Stem Cell Therapeutic Applications Change from 2014-2024?
6. Stem Cell Technologies: Industry Trends, 2014-2024
6.1 Strengths and Weaknesses of The Stem Cell Technologies Market
6.2 Strengths
6.2.1 Stem Cells Are Finally Proving Their Worth
6.3 Weaknesses
6.3.1 Many Difficulties Still to Overcome
6.4 Opportunities and Threats in the Stem Cell Technologies Market
6.4.1 Stem Cells Have Unprecedented Clinical Potential
6.4.2 Regulatory and Commercial Instability Threatens the Field
6.5 STEP Analysis of the Stem Cell Technologies Market, 2014-2024
6.5.1 Social Concerns: A Controversial Technology
6.5.2 Technological Developments: Stem Cell Science Still on the March
6.5.3 Economic Factors: Funding Gaps a Concern
6.5.4 Political Issues: State Attitudes Vital to Research Environment
7. Opinions from Research Interviews
7.1 Dr Robin Smith: Chairman and CEO, NeoStem
7.1.1 The Potential of Stem Cell Therapy
7.1.2 Competition in the Stem Cell Arena
7.1.3 NeoStem’s Products and Technology
7.1.4 Concerns over Stem Cell Therapy
7.1.5 Future Directions for NeoStem and Stem Cell Therapy
7.2 Dr Yael Margolin, President and CEO, Gamida Cell
7.2.1 Stem Cell Therapy and Their Therapeutic Promise
7.2.2 Gamida Cell’s NiCord Product and Umbilical Cord Blood
7.2.3 Partnership with a Leading Pharmaceutical Company
7.2.4 Barriers to Stem Cell Therapy Uptake
8. Conclusions
8.1 The US Leads the Field for Stem Cell Research
8.2 Market Remains Under-Capitalised, in Need of Financing
8.3 Many Barriers Still to Overcome for Companies
8.4 New Entrants to the Market Will Increase Competition



List of Tables
Table 2.1 Aastrom Biosciences: Key Facts, 2014
Table 2.2 Aastrom: Stem Cell Development Pipeline, 2014
Table 2.3 Aastrom: Revenues ($), 2008-2012
Table 2.4 Aastrom: Stem Cell SWOT Analysis, 2014-2024
Table 2.5 Aastrom: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 2.6 Advanced Cell Technology: Key Facts, 2014
Table 2.7 ACT: Stem Cell Development Pipeline, 2014
Table 2.8 ACT: Revenues ($m), 2008-2012
Table 2.9 ACT: Stem Cell SWOT Analysis, 2014-2024
Table 2.10 ACT: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 2.11 Bioheart: Key Facts, 2014
Table 2.12 Bioheart: Stem Cell Development Pipeline, 2014
Table 2.13 Bioheart: Revenues ($m, CAGR %), 2011-2012
Table 2.14 Bioheart: Stem Cell SWOT Analysis, 2014-2024
Table 2.15 Bioheart: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 2.16 BrainStorm Cell Therapeutics: Key Facts, 2014
Table 2.17 BrainStorm Cell Therapeutics: Stem Cell Development Pipeline, 2014
Table 2.18 BrainStorm Cell Therapeutics: Stem Cell SWOT Analysis, 2014-2024
Table 2.19 BrainStorm Cell Therapeutics: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 2.20 California Stem Cells: Key Facts, 2014
Table 2.21 California Stem Cell: Stem Cell Development Pipeline, 2014
Table 2.22 California Stem Cell: Stem Cell SWOT Analysis, 2014-2024
Table 2.23 ISCO: Key Facts, 2014
Table 2.24 ISCO: Stem Cell Development Pipeline, 2014
Table 2.25 ISCO: Revenues ($m, CAGR %), 2011-2012
Table 2.26 ISCO: Stem Cell SWOT Analysis, 2014-2024
Table 2.27 NeoStem: Key Facts, 2014
Table 2.28 NeoStem: Stem Cell Development Pipeline, 2014
Table 2.29 NeoStem: Revenues ($m, CAGR %) by Sector, 2011-2012
Table 2.30 NeoStem: Stem Cell SWOT Analysis, 2014-2024
Table 2.31 NeoStem: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 2.32 Neuralstem: Key Facts, 2014
Table 2.33 Neuralstem: Stem Cell Development Pipeline, 2014
Table 2.34 Neuralstem: Revenues ($m), 2011-2012
Table 2.35 Neuralstem: Stem Cell SWOT Analysis, 2014-2024
Table 2.36 Neuralstem: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 2.37 Medistem: Key Facts, 2014
Table 2.38 Medistem: Stem Cell Development Pipeline, 2014
Table 2.39 Medistem: Stem Cell SWOT Analysis, 2014-2024
Table 2.40 Medistem: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 2.41 Osiris Therapeutics: Key Facts, 2014
Table 2.42 Osiris Therapeutics: Stem Cell Development Pipeline, 2014
Table 2.43 Osiris Therapeutics: Revenues ($m) by Sector, 2008-2012
Table 2.44 Osiris Therapeutics: Stem Cell SWOT Analysis, 2014-2024
Table 2.45 Osiris Therapeutics: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 2.46 Other US Companies Operating in the Stem Cells Technology Industry, 2014
Table 3.1 Apceth: Key Facts, 2014
Table 3.2 Apceth: Stem Cell Development Pipeline, 2014
Table 3.3 Apceth: Stem Cell SWOT Analysis, 2014-2024
Table 3.4 Apceth: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 3.5 Cardio3 BioSciences: Key Facts, 2014
Table 3.6 Cardio3 BioSciences: Stem Cell Development Pipeline, 2014
Table 3.7 Cardio3 BioSciences: Stem Cell SWOT Analysis, 2014-2024
Table 3.8 Cardio3 BioSciences: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 3.9 Cell Cure Neurosciences: Key Facts, 2014
Table 3.10 Cell Cure Neurosciences: Stem Cell Development Pipeline, 2014
Table 3.11 Cell Cure Neurosciences: Stem Cell SWOT Analysis, 2014-2024
Table 3.12 TiGenix: Key Facts, 2014
Table 3.13 TiGenix: Stem Cell Development Pipeline, 2014
Table 3.14 TiGenix: ChondroCelect Revenues ($m, CAGR %), 2010-2012
Table 3.15 TiGenix: ChondroCelect Revenues ($m) and Market Share (%) by Region, 2012
Table 3.16 TiGenix: Stem Cell SWOT Analysis, 2014-2024
Table 3.17 TiGenix: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 3.18 Gamida Cell: Key Facts, 2014
Table 3.19 Gamida Cell: Stem Cell Development Pipeline, 2014
Table 3.20 Gamida Cell: Stem Cell SWOT Analysis, 2014-2024
Table 3.21 Gamida Cell: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 3.22 Pluristem Therapeutics: Key Facts, 2014
Table 3.23 Pluristem Therapeutics: Stem Cell Development Pipeline, 2014
Table 3.24 Pluristem Therapeutics: Revenue ($m, CAGR %), 2012-2013
Table 3.25 Pluristem Therapeutics: Stem Cell SWOT Analysis, 2014-2024
Table 3.26 Pluristem Therapeutics: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 3.27 ReNeuron: Key Facts, 2014
Table 3.28 ReNeuron: Stem Cell Development Pipeline, 2014
Table 3.29 ReNeuron: Revenue ($m, CAGR %), 2012-2013
Table 3.30 ReNeuron: Stem Cell SWOT Analysis, 2014-2024
Table 3.31 ReNeuron: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 3.32 Other European and Israeli Companies Operating in the Stem Cells Technology Industry, 2014
Table 4.1 Anterogen: Key Facts, 2014
Table 4.2 Anterogen: Stem Cell Development Pipeline, 2014
Table 4.3 Anterogen: Stem Cell SWOT Analysis, 2014-2024
Table 4.4 MEDIPOST: Key Facts, 2014
Table 4.5 MEDIPOST: Stem Cell Development Pipeline, 2014
Table 4.6 MEDIPOST: Revenue ($m, CAGR %), 2009-2012
Table 4.7 MEDIPOST: Stem Cell SWOT Analysis, 2014-2024
Table 4.8 MEDIPOST: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 4.9 Mesoblast: Key Facts, 2014
Table 4.10 Mesoblast: Stem Cell Development Pipeline, 2014
Table 4.11 Mesoblast: Revenues ($m) and Change (%), By Sector, 2012-2013
Table 4.12 Mesoblast: Stem Cell SWOT Analysis, 2014-2024
Table 4.13 Mesoblast: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 4.14 Pharmicell: Key Facts, 2014
Table 4.15 Pharmicell: Stem Cell Development Pipeline, 2014
Table 4.16 Pharmicell: Revenues ($m), 2011-2012
Table 4.17 Pharmicell: Stem Cell SWOT Analysis, 2014-2024
Table 4.18 Pharmicell: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 4.19 Stempeutics Research: Key Facts, 2014
Table 4.20 Stempeutics Research: Stem Cell Development Pipeline, 2014
Table 4.21 Stempeutics Research: Stem Cell SWOT Analysis, 2014-2024
Table 4.22 Stempeutics: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Table 5.1 The World Stem Cell Technology Market: Revenue ($m) and Market Share (%) by Therapeutic Application, 2012
Table 5.2 The World Stem Cell Technology Market: Revenue Forecasts ($m, AGR %, CAGR %) by Therapeutic Application, 2013-2024
Table 5.3 The World Stem Cell Technology Market: Market Shares (%) by Therapeutic Application, 2012-2024
Table 6.1 The World Stem Cell Technologies Market: Strengths and Weaknesses, 2014
Table 6.2 The World Stem Cell Technologies Market: Opportunities and Threats, 2014-2024
Table 6.3 The World Stem Cell Technologies Market: STEP Analysis, 2014-2024
List of Figures
Figure 2.1 Aastrom: Revenues ($), 2008-2012
Figure 2.2 Aastrom: Stem Cell Revenue Forecast ($m), 2013-2024
Figure 2.3 ACT: Revenues ($m), 2008-2012
Figure 2.4 ACT: Stem Cell Revenue Forecast ($m), 2013-2024
Figure 2.5 Bioheart: Revenues ($m), 2011-2012
Figure 2.6 Bioheart: Stem Cell Revenue Forecast ($m), 2013-2024
Figure 2.7 BrainStorm Cell Therapeutics: Stem Cell Revenue Forecast ($m), 2013-2024
Figure 2.8 ISCO: Revenues ($m) 2011-2012
Figure 2.9 NeoStem: Revenues ($m) by Sector, 2011-2012
Figure 2.10 NeoStem: Stem Cell Revenue Forecast ($m), 2013-2024
Figure 2.11 Neuralstem: Revenues ($m), 2011-2012
Figure 2.12 Neuralstem: Stem Cell Revenue Forecast ($m), 2013-2024
Figure 2.13 Medistem: Stem Cell Revenue Forecast ($m, AGR %, CAGR %), 2013-2024
Figure 2.14 Osiris Therapeutics: Revenues ($m) by Sector, 2008-2012
Figure 2.15 Osiris Therapeutics: Stem Cell Revenue Forecast ($m), 2013-2024
Figure 3.1 Apceth: Stem Cell Revenue Forecast ($m), 2013-2024
Figure 3.2 Cardio3 BioSciences: Stem Cell Revenue Forecast ($m), 2013-2024
Figure 3.3 TiGenix: ChondroCelect Revenues ($m), 2010-2012
Figure 3.4 TiGenix: Market Share (%) by Region, 2012
Figure 3.5 TiGenix: Stem Cell Revenue Forecast ($m), 2013-2024
Figure 3.6 Gamida Cell: Stem Cell Revenue Forecast ($m), 2013-2024
Figure 3.7 Pluristem Therapeutics: Revenue ($m, CAGR %), 2012-2013
Figure 3.8 Pluristem Therapeutics: Stem Cell Revenue Forecast ($m), 2013-2024
Figure 3.9 ReNeuron: Revenue ($m), 2012-2013
Figure 3.10 ReNeuron: Stem Cell Revenue Forecast ($m), 2013-2024
Figure 4.1 MEDIPOST: Revenue ($m), 2009-2012
Figure 4.2 MEDIPOST: Stem Cell Revenue Forecast ($m), 2013-2024
Figure 4.3 Mesoblast: Revenues ($m), by Sector, 2012-2013
Figure 4.4 Mesoblast: Stem Cell Revenue Forecast ($m), 2013-2024
Figure 4.5 Pharmicell: Revenues ($m), 2011-2012
Figure 4.6 Pharmicell: Stem Cell Revenue Forecast ($m), 2013-2024
Figure 4.7 Stempeutics: Stem Cell Revenue Forecast ($m), 2013-2024
Figure 5.1 The World Stem Cell Technology Market: Market Share (%) by Therapeutic Application, 2012
Figure 5.2 The World Stem Cell Technology Market: Overall Revenue Forecast ($m), 2013-2024
Figure 5.3 The World Stem Cell Technology Market: Drivers and Restraints, 2014-2024
Figure 5.4 The World Stem Cell Technology Market: Revenue Forecasts ($m) by Therapeutic Application, 2013-2024
Figure 5.5 The World Stem Cell Technology Market: Market Shares (%) by Therapeutic Application, 2018
Figure 5.6 The World Stem Cell Technology Market: Market Share (%) by Therapeutic Application, 2024


【掲載企業】

Aastrom Biosciences
Advanced Cell Technology (ACT)
African-Middle East Medical (AFRIMID)
Alkem Laboratories
AlloCure
Alphatec Spine
Amorcyte
Anosis
Anterogen
Antria
Apceth
Athelos Corporation
Athersys
Axiogenesis
Becton-Dickinson
BioCardia
BioE
Biogenea Pharmaceuticals
Bioheart
Biomet Orthopedics
BioTime
Bluebird Bio
BrainStorm Cell Therapeutics
California Stem Cell Inc.
Capricor Therapeutics
Cardio3 BioSciences
Cell Cure Neurosciences
Cell Line Genetics
Cellectis
Cellerant Therapeutics
Celltex Therapeutics
Cellular Dynamics International
CHA Bio & Diostech
Cipla
Cognate BioServices
Cook General BioTechnology
Cryo-Cell International
Cryo-Save
Cytomedix
Cytori Therapeutics
DaVinci Biosciences
Dendreon
Dong-A Pharmaceutical
Drug Controller General of India
Epistem
ERCell LLC
European Medicines Agency (EMA)
Fibrocell Science
Food and Drug Administration (FDA)
Forticell Bioscience
Gamida Cell
Garnet BioTherapeutics
Genzyme
Geron
GlobalStem
Hadassah University Hospital
Harvard Medical School
Health Canada
Human Stem Cells Institute
Immunocellular Therapeutics
Intellicell BioSciences
Intercytex
International Stem Cell Corporation (ISCO)
Intrexon Corporation
Invitrx Therapeutics
InVivo Therapeutics
iPierian
Jules Stein Eye Institute
King's College London
Lentigen
Lifeline Skin Care
Lincoln Park Capital Fund
Lonza
MEDIPOST
Medistem
Merck & Co.
Merck Millipore
Mesoblast
National Academy of Engineering (Korea)
NeoStem
Neuralstem
NeuroGeneration
Novartis
NuVasive
Office of the Chief Scientist (Israel)
OncoCyte
OncoMed Pharma
Orgenesis
OrthoCyte
Osiris Therapeutics
OvaScience
Pharmicell
Plasticell Therapeutics
Pluristem Therapeutics
Progenitor Cell Therapy
Proneuron Biotechnologies
Ramot
ReCyte Therapeutics
Regen BioPharma
Regenerative Sciences
RegenoCELL Therapeutics
ReNeuron
RhinoCyte
Roslin Cellab
Rush University Medical Center
SanBio
Saneron CCEL Therapeutics
Sanofi
Schepens Eye Research Institute
South Korea Food and Drug Administration (SFDA)
Stem Cell Medicine
Stem Cell Sciences
StemCells
Stemcyte
Stemedica Cell Technologies
Stemline Therapeutics
Stempeutics Research
Stratatech Corporation
Targazyme (formerly America Stem Cell, Inc.)
TCA Cellular Therapy
Technology Strategy Board (UK)
Tel Aviv University
Teva Pharmaceuticals
The Isar Medical Centre
TiGenix
Tissue Genesis
United Therapeutics
US Department of Defence
US National Academy of Sciences
Vesta Therapeutics
ViaCyte
VistaGen
Vital Therapies
Vitro Biopharma
Wizbang Technologies
World Health Organization (WHO)


★調査レポート[主要な幹細胞（ステムセル）技術企業分析（2014-2024）] ( Pharma Leader Series: Top Stem Cell Technology Companies 2014-2024 / Visiongain-4052643) 販売に関する免責事項
[主要な幹細胞（ステムセル）技術企業分析（2014-2024）] ( Pharma Leader Series: Top Stem Cell Technology Companies 2014-2024 / Visiongain-4052643) についてEメールでお問い合わせ
◆関連調査資料◆
  • 世界のワクチン製造技術およびサービス市場（2014-2024）
  • 世界のセルベースアッセイ（Cell-based Assay）市場（2014-2024）
  • トランスレーショナル再生医療市場（2014-2024）
  • 医療用バイオバンキング市場（2014-2024）
  • 次世代バイオロジックス（生物製剤）市場：技術、産業、市場（2014-2024）
  • 先進創傷ケア製品のグローバル市場（2014-2024）
  • 治療応用のためのRNAi：技術および市場（2014-2024）
  • 幹細胞治療技術及び用途の世界市場
  • 世界の前立腺がん治療市場予測：前立腺がん治療薬、前立腺がん治療デバイス
  • CNS(中枢神経系)疾病の向けオーファンドラッグ：R&Dおよび市場（2014-2024）

    • ◆H&Iグローバルリサーチ株式会社のお客様（例）◆